(Q33848437)

English

The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer? (English)

1 reference

Europe PubMed Central

29 July 2017

magnetic resonance imaging

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

7

object named as

Mark Emberton

1 reference

Europe PubMed Central

29 July 2017

author name string

Mohamed Abd-Alazeez

1

1 reference

Europe PubMed Central

29 July 2017

Hashim U Ahmed

2

1 reference

Europe PubMed Central

29 July 2017

Manit Arya

3

1 reference

Europe PubMed Central

29 July 2017

Susan C Charman

4

1 reference

Europe PubMed Central

29 July 2017

Eleni Anastasiadis

5

1 reference

Europe PubMed Central

29 July 2017

Alex Freeman

6

1 reference

Europe PubMed Central

29 July 2017

Alex Kirkham

8

1 reference

Europe PubMed Central

29 July 2017

publication date

18 September 2013

1 reference

Europe PubMed Central

29 July 2017

Urologic Oncology

1 reference

Europe PubMed Central

29 July 2017

32

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

45.e17-22

1 reference

Europe PubMed Central

29 July 2017

Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

ESUR prostate MR guidelines 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

How good is MRI at detecting and characterising cancer within the prostate?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

5 July 2018

Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082533

29 October 2018

Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Dynamic Contrast Enhanced, Pelvic Phased Array Magnetic Resonance Imaging of Localized Prostate Cancer for Predicting Tumor Volume: Correlation With Radical Prostatectomy Findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Characterizing clinically significant prostate cancer using template prostate mapping biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.007

7 January 2021

Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24055430

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24055430

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.UROLONC.2013.06.007

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33848437&oldid=1856109158"